看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。' s( A% w4 }5 z( _+ w
& A, e9 X' i: t; ^
& p& b% N. u" H" X# iCurrently available feasibility data for possible combination strategies. 0 G- e3 y1 r- V" C9 G" P- S& w
————————————————————————————————
. U7 V' n: t2 c' i# f9 M( mCombination Feasibility according to preliminary data
$ }& b6 \4 B i: H$ k5 g——————————————————————————————————! r) d: _6 O6 L) g5 y& `
Bevacizumab + sorafenib Yes, reduced dose
+ n7 a& S$ X9 ^5 LBevacizumab + sunitinib† No ' J; ~4 X* w: M
Bevacizumab + temsirolimus Yes
. `8 W; a) n8 \3 S$ t$ ZBevacizumab + everolimus Yes
+ U$ s5 |, m" z jSorafenib + sunitinib ? - W* h/ P9 [- E1 A* v3 F
Sorafenib + temsirolimus Yes, reduced dose " @' X% ?& x! K1 O7 L- W
Sorafenib + everolimus Yes, reduced dose & ^+ W: y( \. h
Sunitinib + temsirolimus† No
; T* `! i- {0 P8 T* I& tSunitinib + everolimus ? - i6 f' W0 L4 Z6 { u% X0 X5 A
Temsirolimus + everolimus ? ' r3 V) _# ~! }
————————————————————
0 m s$ `* p: a- I) N†Led to US FDA warning.+ d$ o0 ~' J! L
?: As yet unattempted combination.# l* q. |) y5 j
|